Abstract
Parkinson's disease (PD) is primarily a disease of elderly patients. Is a multifaceted disorder comprised of both motor and non-motor symptoms at all stages of the disease. This review seeks to integrate data from the newest treatment options with data from established therapies, so as to provide an up-to- date evidence-based reference for clinicians treating early PD, with medications that can be used as an alternative to levodopa. The clinicians' approach to the treatment of early Parkinson's disease (PD) should take into account numerous aspects, including how to inform a patient upon diagnosis and the critical decision of what therapy to adopt and when to start it. The treatment of the motor disorder associated with early PD needs to consider several crucial factors, such as age at onset, comorbidities, and the patient's functional requirements, and cannot be summarized in a simple formula. In younger patients (i.e., before the age of 70) and in those without high functional requirements, treatment is usually initiated with dopamine agonists and/or monoamine oxidase-B enzyme inhibitors (MAO-B I). In younger patients, levodopa should be added to dopamine agonists and/or MAO-B I, as required by disease progression, whereas in older patients, when response to levodopa alone is not satisfactory, dopamine agonists or catechol-O- methyltransferase inhibitors may subsequently be added.
References
Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, et al. Treatment of early Parkinson's disease. Part 1. Eur Neurol. 2009;61(4):193-205.
Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ, et al. Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Neurology. 2006;66(7):976-82.
Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013;20(1):16-34.
Fox SH, Katzenschlager R, Lim S-Y, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248-66.
Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine 3-hydroxytyramine in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr. 1960;38:1236-9.
Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism - chronic treatment with L-Dopa. N Engl J Med. 1969;280(7):337-45.
Kim HJ, Jeon BS, Jenner P. Hallmarks of treatment aspects: Parkinson's disease throughout centuries including l-Dopa. Int Rev Neurobiol. 2017;132:295-343.
Laurencin C, Danaila T, Broussolle E, Thobois S. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited. Rev Neurol (Paris). 2016;172(8-9):512-23.
Stocchi F, Vacca L, Radicati FG. How to optimize the treatment of early stage Parkinson's disease. Transl Neurodegener. 2015;4(1):4.
Marsden CD, Parkes JD. Success and problems of longterm levodopa therapy in Parkinson's disease. Lancet (London) 1977;1(8007):345-9.
Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, et al. A multicentre longitudinal observational study of changes in self-reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2006;78(5):465-9.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A Double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-78.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-508.
Hauser RA. Early pharmacologic treatment in Parkinson's disease. Am J Manag Care. 2010;S100-7.
Moreno C, Bernal O, Rueda M. Manejo integral de la enfermedad de Parkinson en Colombia. Acta Neurológica Colomb. 2014;3(S1):1-35.
Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11 Supl- 5):S1-88.
Muzerengi S, Clarke CE. Initial drug treatment in Parkinson's disease. BMJ.;351:h4669
Marsili L, Marconi R, Colosimo C. Treatment strategies in early Parkinson's disease. En: International review of neurobiology. 2017. p. 345-60. Disponible en: http://wwwncbi.nlm.nih.gov/pubmed/28554414
Moreno López CL, Bernal Pacheco O, Barrios Vincos G, Arango Uribe G, Cerquera Cleves C, Orozco Vélez JL, et al. Consenso de la Asociación Colombiana de Neurología sobre el uso de apomorfina en la enfermedad de Parkinson. Acta Neurológica Colomb [Internet]. 2018;34(1):25-39.
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361:k1315.
Tomlinson CL, Herd CP, Clarke CE, Meek C, Patel S, Stowe R, et al. Physiotherapy for Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev. 2014;(6):CD002815.
Mehrholz J, Kugler J, Storch A, Pohl M, Hirsch K, Elsner B. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev. 2015;(9):CD007830.
Saltychev M, Bärlund E, Paltamaa J, Katajapuu N, Laimi K. Progressive resistance training in Parkinson's disease: a systematic review and meta-analysis. BMJ Open. 2016;6(1):e008756.
Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. 2013;(9):CD002817.
Yang Y, Li X-Y, Gong L, Zhu Y-L, Hao Y-L. Tai Chi for improvement of motor function, balance and gait in Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2014;9(7):e102942.
de Dreu MJ, van der Wilk ASD, Poppe E, Kwakkel G, van Wegen EEH. Rehabilitation, exercise therapy and music in patients with Parkinson's disease: a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism Relat Disord [Internet]. 2012;18:S114-9.
Foster ER, Bedekar M, Tickle-Degnen L. Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson's disease. Am J Occup Ther. 2014 ;68(1):39-49.
van Hooren MRA, Baijens LWJ, Voskuilen S, Oosterloo M, Kremer B. Treatment effects for dysphagia in Parkinson's disease: A systematic review. Parkinsonism Relat Disord. 2014;20(8):800-7.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.